No single NIPT test is definitively “the best” for every pregnancy. All major NIPT brands detect Down syndrome (trisomy 21) with sensitivity above 99% and specificity above 99.9%, so the differences between them come down to methodology, how they handle special situations like twins or higher body weight, and what additional screening they offer beyond the three common trisomies.
The Major NIPT Brands
Four tests dominate the U.S. market. MaterniT21 Plus (from Sequenom, now part of LabCorp) and the Verifi test (from Illumina) both use whole genome sequencing, meaning they read fragments of DNA across the entire genome to look for extra copies of chromosomes. The Harmony Prenatal Test (from Ariosa Diagnostics, now also under Roche) uses a targeted sequencing approach. The Panorama Prenatal Test (from Natera) uses a different method entirely, analyzing specific genetic markers called single nucleotide polymorphisms (SNPs) to distinguish fetal DNA from maternal DNA.
The Prequel test from Myriad and QNatal Advanced from Quest Diagnostics are also available, expanding your options further. Your OB or midwife typically works with one or two labs, which often narrows the choice for you in practice.
How Accuracy Compares Across Tests
For the three conditions NIPT is primarily designed to catch, the numbers are reassuringly similar across all platforms. In a study of nearly 147,000 pregnancies, NIPT detected trisomy 21 with 99.2% sensitivity, trisomy 18 with 98.2% sensitivity, and trisomy 13 with 100% sensitivity. Specificity for all three was above 99.95%, meaning false positives are rare regardless of which brand you choose.
Where differences emerge is in the positive predictive value, which tells you how likely a “high risk” result is to be a true positive. A 2024 systematic review found that whole genome sequencing methods had higher positive predictive values than SNP-based methods like Panorama. In plain terms, if you get a high-risk result from a whole genome sequencing test, it’s somewhat more likely to be confirmed as a true finding than a high-risk result from an SNP-based test. That said, ACOG is clear that any positive NIPT result should be confirmed with diagnostic testing (amniocentesis or CVS) before making decisions.
Whole Genome vs. SNP-Based Methods
The biggest technical distinction between tests is their underlying method. Whole genome sequencing (used by MaterniT21 Plus and Verifi) reads DNA broadly, counting fragments from every chromosome. This approach has a simpler lab workflow, lower failure rates, and can potentially detect a wider range of abnormalities. SNP-based analysis (used by Panorama) zeroes in on thousands of specific genetic markers to distinguish the baby’s DNA from the mother’s, then looks for patterns suggesting extra or missing chromosomes.
Each approach has trade-offs. SNP-based testing can determine whether twins are identical or fraternal and can estimate the fetal fraction for each twin individually, which matters for accuracy. It can also detect triploidy, a rare condition where the baby has a complete extra set of chromosomes, which counting-based methods generally miss. On the other hand, SNP-based platforms don’t work when donor eggs or surrogacy are involved, because the method relies on comparing parental and fetal genetic profiles. Whole genome sequencing doesn’t have this limitation.
Why Body Weight Matters
All NIPT tests analyze fragments of fetal DNA circulating in the mother’s blood, and the proportion of that DNA (called fetal fraction) needs to be high enough for reliable results. Most tests require a fetal fraction of roughly 2% to 4%. Higher maternal BMI is associated with lower fetal fraction because a larger blood volume dilutes the fetal signal.
For women with significant obesity, test failure rates can climb as high as 24.3% on platforms that impose a strict fetal fraction cutoff. If the test can’t reach that threshold, you get a “no result” and may need to redraw later or pursue a different screening approach. Some whole genome sequencing workflows have been designed to function without a hard fetal fraction cutoff, maintaining sensitivity above 94% even for women with class III obesity (BMI over 40). If your BMI is above 35, it’s worth asking your provider which platform they use and how it handles low fetal fraction.
Twin Pregnancies and Donor Eggs
NIPT works in twin pregnancies, but with caveats. Failure rates in twins range from 1.6% to 13.2%, with a median of 3.6%, compared to roughly 1% to 3% in singletons. The challenge is that fraternal twins each contribute their own fetal fraction, and one twin may contribute very little DNA, leading to a missed finding or a failed test.
SNP-based platforms like Panorama can assess each twin’s fetal fraction individually and determine zygosity, which gives more granular information. Counting-based methods that only measure a combined fetal fraction may be less reliable for fraternal twins specifically. However, if your pregnancy involved donor eggs, the SNP approach won’t work because the donor’s genetic contribution confuses the algorithm that distinguishes maternal from fetal DNA. In that case, a counting-based platform is the better fit.
Pregnancies with a vanishing twin (a twin that stopped developing early) can also cause inaccurate results on any platform, because DNA from the nonviable twin may still circulate in the mother’s blood for weeks.
Microdeletion Screening: Proceed With Caution
Several NIPT brands offer optional screening for microdeletions, which are small missing segments of chromosomes. The most commonly screened is 22q11.2 deletion (DiGeorge syndrome). This is where the gap between marketing and reality is widest.
The positive predictive value for 22q11.2 microdeletion screening varies wildly depending on the study, from as low as 6.6% to as high as 72%. In one dataset, only 7 out of 52 positive microdeletion screens were confirmed as true positives (a PPV of 13.4%). That means the majority of “high risk” results for microdeletions turn out to be false alarms. ACOG does not recommend routine microdeletion screening for the general population and states that patients interested in this information should be offered diagnostic testing instead. If you’re considering the microdeletion add-on, understand that a positive result is far more likely to be wrong than right and will almost certainly require invasive follow-up testing to clarify.
When You Can Test
Most NIPT brands are validated starting at 10 weeks of gestation. Before that point, fetal fraction is generally too low to produce reliable results. Some providers will draw blood at 9 weeks, but the chance of needing a redraw increases. There’s no meaningful difference between brands on timing, so 10 weeks is the practical starting point regardless of which test you choose.
Cost and Insurance Coverage
Insurance coverage for NIPT varies significantly by plan. Cigna covers NIPT for any viable single pregnancy at or beyond 10 weeks with no age or risk restrictions. UnitedHealthcare covers it when traditional risk factors are present (maternal age 35 or older, abnormal ultrasound, prior trisomy pregnancy, positive first or second trimester screening) or after shared decision-making counseling with a provider. Molina Healthcare requires both genetic counseling and at least one clinical risk factor. Aetna lists all the major brands by name as coverable.
Out-of-pocket costs without insurance typically range from $250 to $600, though most labs offer cash-pay pricing or financial assistance programs. Natera, for instance, advertises a cash price cap for uninsured patients. If cost is a concern, call the lab directly before your blood draw to confirm what you’ll owe.
Choosing the Right Test for Your Situation
For a straightforward singleton pregnancy, all major NIPT platforms perform comparably for trisomy 21, 18, and 13 screening. Your provider’s lab partnership will likely determine which test you get, and that’s fine. The clinical differences are marginal for most patients.
A few situations do favor one approach over another. If you’re carrying twins, an SNP-based test like Panorama can assess each twin individually and determine zygosity. If your pregnancy involved donor eggs or surrogacy, a counting-based whole genome method is necessary because SNP platforms can’t handle the mismatched genetic profiles. If your BMI is above 35 or 40, ask about a platform optimized for low fetal fraction to reduce your chance of a failed test. And if your provider offers microdeletion screening as an add-on, weigh the high false-positive rate against the anxiety a positive result would cause before opting in.